Dr. Axe Wire · Study decoded · health

Most Over-The-Counter Vulvar Soothing Products Contain Hidden Contact Allergens

A new analysis finds labels like natural and hypoallergenic do not mean a vulvar product is less likely to irritate sensitive skin.

By Dr. Axe Editorial Team · October 24, 2026 · 1 source · Watch

Photo: Pexels

An analysis published October 20, 2026 in Menopause found that 78% of over-the-counter vulvar soothing products contained at least one contact allergen, and labels like natural or hypoallergenic did not predict a cleaner ingredient list.

Researchers screened 65 over-the-counter, nonhormonal vulvar soothing products sold through major US retailers, checking each ingredient list against the North American Contact Dermatitis Group's 80-allergen series. Overall, 78% of products contained at least one known contact allergen and 49% contained an allergen derived from a botanical ingredient. Fragrance ingredients were the most common allergen, appearing in 39% of products, followed by sodium benzoate in 25%, phenoxyethanol in 12%, and propylene glycol in 9%. Twenty-eight percent of products labeled 'fragrance-free' still contained a botanical scent allergen, and every single product marketed as 'hypoallergenic' contained at least one allergen. Ointments carried a lower allergen burden than other formulations such as creams or gels, while price was not linked to allergen burden.

Marketing terms on personal care labels are not regulated the way clinical or allergen-testing claims are, so a word like natural or clean describes positioning rather than a verified ingredient standard. Vulvar skin is thinner and more absorbent than skin elsewhere on the body, which can make contact allergens there more likely to be associated with irritation or dermatitis. The authors state these findings support ingredient-based counseling by menopause-trained clinicians when recommending over-the-counter vulvar products, rather than relying on front-of-label claims.

Share of Vulvar Soothing Products Containing Each Allergen Type

65 products analyzed

Any contact allergen

78 %

Botanical-derived allergen

49 %

Fragrance ingredients

39 %

Sodium benzoate

25 %

Phenoxyethanol

12 %

Menopause, 2026, McAleer et al.

This was a cross-sectional ingredient audit of products on the shelf, not a study that tracked which users actually developed reactions, so an allergen's presence in a formula is linked to potential irritation, not a measured rate of dermatitis in real use. This shows a link, not proof that any single ingredient causes a reaction.

Dr. Axe’s Take

I look past marketing words like natural, clean and hypoallergenic, and this analysis confirms why: none tracked with lower allergen counts. Fragrance, even botanical, was the biggest offender. If you use a soothing product on sensitive vulvar skin, especially during menopause when tissue is thinner and more reactive, read the ingredient list for fragrance, sodium benzoate, phenoxyethanol and propylene glycol rather than trusting the label. This week, I would switch to a short-ingredient, fragrance-free ointment, since ointments showed a lower allergen burden, and patch-test new products first.

— Dr. Axe

Take the Cellular Health Quiz →

Study summary

Who: 65 over-the-counter, nonhormonal vulvar soothing products sold through major US retailers
Design: cross-sectional ingredient analysis against an 80-allergen contact dermatitis reference panel
Dose: Not applicable; this was a product ingredient audit, not a dosing study
Primary result: 78% of products contained at least one contact allergen; 49% contained a botanical-derived allergen
Secondary: Fragrance in 39%; sodium benzoate in 25%; phenoxyethanol in 12%; propylene glycol in 9%; 28% of 'fragrance-free' products had a botanical scent allergen; all 'hypoallergenic' products had an allergen; ointments had a lower allergen burden than other vehicles
Funding / conflicts: Conflict statement in the PubMed record: Financial disclosure/Conflicts of interest: M.M.M. volunteers on the board of directors of the Women’s Dermatological Society and Vulvar Dermatoses Research Consortium, is a consultant for LEO Pharma and an investigator for Incyte, and receives ongoing institutional funding from Galderma. The other authors have nothing to disclose. Funding not reported in the abstract.
Date: Oct 20, 2026